New insights into HBV replication: New opportunities for improved therapies

Future Virology

Volumn 4, Issue 1, 2009, Pages 55-70

  Nassal, Michael ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Anti HBV drugs; Assembly inhibitors; Capsid; Chronic hepatitis B; Covalently closed circular DNA; Crossresistance; Drug resistance; Hepadnavirus; Nucleos(t)ide analogs; Protein priming; Protein primed reverse transcription; Viral persistence

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS X PROTEIN; HEPATITIS E ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2B INTERFERON; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIREAD R;

CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; DNA METABOLISM; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION REGULATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL; PATHOGENICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW; TREATMENT RESPONSE; TURNOVER TIME; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS CAPSID; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALIA; HEPADNAVIRIDAE; HEPATITIS B VIRUS; MIRIDAE;

EID: 70349215530     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.4.1.55     Document Type: Review

References (147)

1. Lai CL, Ratziu V, Yuen MF, Poynard T: Viral hepatitis B. Lancet 362(9401), 2089-2094 (2003).
2. Lavanchy D: Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J. Clin. Virol. 34(Suppl. 1), S1-S3 (2005).
3. Zuckerman JN: Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J. Med. Virol. 78(2), 169-177 (2006).
4. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45(4), 529-538 (2006).
5. Menne S, Cote PJ: The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J. Gastroenterol. 13(1), 104-124 (2007).
6. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J. Virol. 79(15), 9369-9380 (2005).
7. Chen M, Sällberg M, Hughes J et al.: Immune tolerance split between hepatitis B virus precore and core proteins. J. Virol. 79(5), 3016-3027 (2005).
8. Visvanathan K, Skinner NA, Thompson AJ et al.: Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 45(1), 102-110 (2007).
9. Crispe IN: Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 3(1), 51-62 (2003).
10. Glebe D, Urban S: Viral and cellular determinants involved in hepadnaviral entry. World J. Gastroenterol. 13(1), 22-38 (2007).
11. Urban S: New insights into hepatitis B and hepatitis-δ virus entry. Future Virology 3(3), 253-264 (2008).
12. Mason WS, Jilbert AR, Summers J: Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc. Natl Acad. Sci. USA 102(4), 1139-1144 (2005).
13. Ganem D, Prince AM: Hepatitis B virus infection: natural history and clinical consequences. N. Engl. J. Med. 350(11), 1118-1129 (2004).
14. Guidotti LG, Chisari FV: Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 1, 23-61 (2006).
15. Iannacone M, Sitia G, Guidotti LG: Pathogenetic and antiviral immune responses against hepatitis B virus. Future Virology 1(2), 189-196 (2006).
16. Chen CJ, Yang HI, Su J et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1), 65-73 (2006).
17. Iloeje UH, Yang HI, Jen CL et al.: Risk and predictors of mortality associated with chronic hepatitis B infection. Clin. Gastroenterol. Hepatol. 5(8), 921-931 (2007).
18. Pawlotsky JM, Dusheiko G, Hatzakis A et al.: Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 134(2), 405-415 (2008).
19. Dienstag JL, Schiff ER, Wright TL et al.: Lamivudine as initial treatment for chronic hepatitis B in the USA. N. Engl. J. Med. 341(17), 1256-1263 (1999).
20. Marcellin P, Chang TT, Lim SG et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348(9), 808-816 (2003).
21. Gish RG, Lok AS, Chang TT et al.: Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133(5), 1437-1444 (2007).
22. Lai CL, Gane E, Liaw YF et al.: Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357(25), 2576-2588 (2007).
23. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS: Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J. Hepatol. 48(3), 391-398 (2008).
24. Lok AS: Navigating the maze of hepatitis B treatments. Gastroenterology 132(4), 1586-1594 (2007).
25. Janssen HL, van Zonneveld M, Senturk H et al.: Pegylated IFN-α-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365(9454), 123-129 (2005).
26. Lau GK, Piratvisuth T, Luo KX et al.: PegIFN-α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352(26), 2682-2695 (2005).
27. Kau A, Vermehren J, Sarrazin C: Treatment predictors of a sustained virologic response in hepatitis B and C. J. Hepatol. 49(4), 634-651 (2008).
28. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ: Therapeutic strategies in the management of patienis with chronic hepatitis B virus infection. Lancet Infect. Dis. 8(3) 167-178 (2008).
29. Hadziyannis SJ: Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Expert Opin. Investig. Drugs 16(6), 777-786 (2007).
30. Palumbo E: Hepatitis B genotypes and response to antiviral therapy: a review. Am. J. Ther. 14(3), 306-309 (2007).
31. Aguiar RS, Peterlin BM: APOBEC3 proteins and reverse transcription. Virus Res. 134(1-2), 74-85 (2008).
32. Locarnini S, Mason WS: Cellular and virological mechanisms of HBV drug resistance. J. Hepatol. 44(2), 422-431 (2006).
33. Ghany M, Liang TJ: Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 132(4), 1574-1585 (2007).
34. Tenney DJ, Rose RE, Baldick CJ et al.: Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother. 51(3), 902-911 (2007).
35. Baldick CJ, Tenney DJ, Mazzucco CE et al.: Comprehensiire evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 47(5), 1473-1482 (2008).
36. Hsia CC, Purcell RH, Farsshid M, Lachenbruch PA, Yu MY: Quantification of hepatitis B virus gehomes and infectivity in human serum samples. Transfusion 46(10), 1829-1835 (2006).
37. Nassal M, Dallmeier K, Schultz U, Sun D: Phenotyping hepatitis B virus variants: from transfection towards a small animal in vivo infection model. J. Clin. Virol. 34(Suppl. 1), S89-S95 (2005).
38. Beterams G, Nassal M: Significant interference with hepatitis B virus replication by a core-nuclease fusion protein. J. Biol. Chem. 276(12), 8875-8883 (2001).
39. Grimm D, Streetz KL, Jopling CL et al.: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441(7092), 537-541 (2006).
40. Lu M, Menne S, Yang D, Xu Y, Roggendorf M: Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model. Expert Opin. Investig. Drugs 16(6), 787-801 (2007).
41. Dallmeier K, Nassal M. Hepadnaviruses have a narrow host range: do they? In: Comparative Hepatitis. Weber O, Protzer U (Eds). Birkhäuser, Basel, Boston, Berlin (2008).
42. Köck J, Nassal M, MacNelly S, Baumert TF, Blum HE, von Weizsäcker F: Efficient infection of primary tupaia hepatocytes with purified human and wolly monkey hepatitis B virus. J. Virol. 75(11), 5084-5089 (2001).
43. Schultz W, Grgacic E, Nassal M: Duck hepatitis B virus: an invaluable model system for HBV infection. Adv. Virus Res. 63, 1-70 (2004).
44. Dryden KA, Wieland SF, Whitten-Bauer C, Gerin JL, Chisari FV, Yeager M: Native hepatitis B virions and capsids visualized by electron cryomicroscopy. Mol. Cell 22(6), 843-850 (2006).
45. Seitz S, Urban S, Antoni C, Bottcher B: Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions. EMBO J. 26(18), 4160-4167 (2007).
46. Schulze A, Gripon P, Urban S: Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 46(6), 1759-1768 (2007).
47. Kann M, Schmitz A, Rabe B: Intracellular transport of hepatitis B virus. World J. Gastroenterol. 13(1), 39-47 (2007).
48. Beck J, Nassal M: Hepatitis B virus replication. World J. Gastroenterol. 13(1), 48-64 (2007).
49. Nassal M: Hepatitis B viruses: reverse transcription a different way. Virus Res. 134(1-2), 235-249 (2008).
50. Tuttleman JS, Pourcel C, Summers J: Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47(3), 451-460 (1986).
51. Le Mire MF, Miller DS, Foster WK, Burrell CJ, Jilbert AR: Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection. J. Virol. 79(19), 12242-12252 (2005).
52. Bruss V: Hepatitis B virus morphogenesis. World J. Gastroenterol. 13(1), 65-73 (2007).
53. Lambert C, Doring T, Prange R: Hepatitis P virus maturation is sensitive to functional inhibition of ESCRT-III, Vps4, and γ-2-adaptin. J. Virol. 81(17), 9050-9060 (2007).
54. Witanabe T, Sorensen EM, Naito A, Schott M, Kim S, Ahlquist P: Involvement of host cellular multivesicular body functions in hepatitis B virus budding. Proc. Natl Acad. Sci. USA 104(24), 10205-10210 (2007).
55. Gerlich WH, Robinson WS: Hepatitis B Virus contains protein attached to the 5′ terminus of its complete DNA strand. Cell 21(3), 801-809 (1980).
56. Bartenschlager R, Schaller H: The amino- terminal domain of the hepadnaviral P-gene encodes the terminal protein (genome-linked protein) believed to prime reverse transcription. EMBO J. 7(13), 4185-4192 (1988).
57. Wang GH, Seeger C: The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell 71(4), 663-670 (1992).
58. Junker-Niepmann M, Bartenschlager R, Schaller H: A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J. 9(10), 3389-3396 (1990).
59. Knaus T, Nassal M: The encapsidation signal on the hepatitis B virus RNA pregenome forms a stem-loop structure that is critical for its function. Nucleic Acids Res. 21(17). 3967-3975 (1993).
60. Pollack JR, Ganem D: An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation. J. Virol. 67(6), 3254-3263 (1993).
61. Wang GH, Seeger C: Novel mechanism for reverse transcription in hepatitis B viruses. J. Virol. 67(11), 6507-6512 (1993).
62. Tavis JE, Perri S, Ganem D: Hepadnavirus reverse transcription initiates within the stem-loop of the RNA packaging signal and employs a novel strand transfer. J. Virol. 68(6), 3536-3543 (1994).
63. Wang GH, Zoulim F, Leber EH, Kitson J, Seeger C: Role of RNA in enzymatic activity of the reverse transcriptase of hepatitis B viruses. J. Virol. 68(12), 8437-8442 (1994).
64. Nassal M, Rieger A: A bulged region of the hepatitis B virus RNA encapsidation signal contains the replication origin for discontinuous first-strand DNA synthesis. J. Virol. 70(5), 2764-2773 (1996).
65. Abraham TM, Loeb DD: The topology of hepatitis-B virus pregenomic RNA promotes its replicatton. J. Virol. 81(21), 11577-11584 (2007).
66. Lewellyn EB, Loeb DD: Base pairing between cis-acting sequences contributes to template switching during plus-strand DNA synthesis in human hepatitis B virus. J. Virol. 81(12), 6207-6215 (2007).
67. Hu J, Seeger C: Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc. Natl Acad. Sci. USA 93(3), 1060-1064 (1996).
68. Hu J, Toft DO, Seeger C: Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids EMBO J. 16(1), 59-68 (1997).
69. Hard FU, Hayer-Hard M: Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295 (5561), 1852-1858 (2002).
70. Mayer MP, Bukau B: Hsp70 chaperones: cellular functions and molecular mechanism. Cell. Mol. Life Sci. 62(6), 670-684 (2005).
71. Hu. J, Toft D, Anselmo D, Wang X: In vitro reconstitution of functional hepadnavirus reverse transcriptase with cellular chaperone proteins. J. Virol. 76(1), 269-279 (2002).
72. Beck J, Nassal M: Efficient Hsp90- independent in vitro activation by Hsc70 and Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client protein. J. Biol. Chem. 278(38), 36128-36138 (2003).
73. Stahl M, Retzlaff M, Nassal M, Beck J: Chaperone activatiod of the hepadnaviral reverse transcriptase for template RNA binding is established by the Hsp70 and stimulated by the Hsp90 system. Nucleic Acids Res. 35(18), 6124-6136 (2007).
74. Stahl M, Beck J, Nassal M: Chaperones activate hepadnavirus reverse transcriptase by transiently exposing a C-proximal region in the terminal protein domain that contributes to epsilon RNA binding. J. Virol. 81(24), 13354-13364 (2007).
75. Beck J, Nassal M: Formation of a functional hepatitis B virus replication initiation complex involves a major structural alteration in the RNA template. Mol. Cell. Biol. 18(11), 6265-6272 (1998).
76. Tavis JE, Massey B, Gong Y. The duck hepatitis B virus polymerase is activated by its RNA packaging signal, epsilon. J. Virol. 72(7), 5789-5796 (1998).
77. Hu J, Flores D, Toft D, Wang X, Nguyen D: Requirement of heat shock protein 90 for human-hepatitis B virus reverse transcriptase function. J. Virol. 78(23), 13122-13131 (2004).
78. Hu J, Boyer M: Hepatitis B virus reverse transcriptase and epsilon RNA sequences required for specific interaction in vitro. J. Virol. 80(5), 2141-2150 (2006).
79. Girard FC, Ottink OM, Ampt KA, Tessari M, Wijmenga SS: Thermodynamics and NMR studies on duck, heron and human HBV encapsidation signals. Nucleic Acids Res. 35 (8), 2800-2811 (2007).
80. Beck J, Vogel M, Nassal M: dNTP versus NTP discrimination by phenylalanine 451 in duck hepatitis B virus P protein indicates a common structure of the dNTP-binding pocket with other reverse transcriptases. NucleicAcids Res. 30(7), 1679-1687 (2002).
81. Kim HY, Kim HY, Jung J, Park S, Shin HJ, Kim K: Incorporation of deoxyribonucleotides and ribonucleotides by a dNTP-binding cleft mutated reverse transcriptase in hepatitis B virus core particles. Virology 370 (1), 205-212 (2008).
82. Le Guerhier F, Thermet A, Guerret S et a.l: Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model. J. Hepatol. 38 (3), 328-334 (2003).
83. Feld JJ, Colledge D, Sozzi V, Edwards R, Littlejohn M, Locarnini SA: The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res. 76(2), 168-177 (2007).
84. Lin L, Hu J: Inhibition of hepadnavirus reverse transcriptase-epsilon RNA interaction by porphyrin compounds. J. Virol. 82(5), 2305-2312 (2008).
85. Wang X, Qian X, Guo HC, Hu J: Heat shock protein 90-independent activation of truncated hepadnavirus reverse transcriptase. J. Virol. 7(8), 4471-4480 (2003).
86. Lin L, Wan F, Hu J: Functional and structural dynamics of hepadnavirus reverse transcriptase during protein-primed initiation of reverse transcription: effects of metal ions. J. Virol. 82(12), 5703-5714 (2008).
87. Das K, Xiong X, Yang H et al.: Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J. Virol. 75(10), 4771-4779 (2001).
88. Bartholomeusz A, Tehan BG, Chalmers DK: Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir. Ther. (Lond.) 9(2), 149-160 (2004).
89. Steven AC, Conway JF, Cheng N et al.: Structure, assembly, and antigenicity of hepatitis B virus capsid proteins. Adv. Virus Res. 64, 125-164 (2005).
90. Crowther RA, Kiselev NA, Böttcher B et al.: Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy. Ce11 77(6), 943-950 (1994).
91. Kenney JM, von Bonsdorff CH, Nassal M, Fuller SD: Evolutionary conservation in the hepatitis B virus core structure: comparison of human and duck cores. Structure 3(10), 1009-1019 (1995).
92. Böttcher B, Wynne SA, Crowther RA: Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy. Nature 386 (6620), 88-91 (1997).
93. Conway JF, Cheng N, Zlotnick A, Wingfield PT, Stahl SJ, Steven AC: Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy. Nature 386(6620), 91-94 (1997).
94. Wynne SA, Crowther RA, Leslie AG: The crystal structure of the human hepatitis B virus capsid. Mol. Cell 3(6), 771-780 (1999).
95. Böttcher B, Vogel Y, Floss M; Nassal M: High plasticity of the hepatitis B virus capsid revealed by conformational stress. J. Mol. Biol. 356(3), 812-822 (2006).
96. Birnbaum F, Nassal M: Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein. J. Virol. 64(7), 3319-3330 (1990).
97. Watts NR, Conway JF, Cheng N et al.: The morphogenic linker peptide of HBV capsid protein forms a mobile array on the interior surface. EMBO J. 21(5), 876-884 (2002).
98. Nassal M: The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly. J. Virol. 66(7), 4107-4116 (1992).
99. Nassal M, Leifer I, Wingert I, Dallmeier K, Prinz S, Vorreiter J: A stnictutul model for duck hepatitis B virus core protein derived by extensive mutagenesis. J. Virol. 81(23), 13218-13229 (2007).
100. Zhou S, Standring DN: Hepatitis B virus capsid particles are assembled from core-protein dimer precursors. Proc. Natl Acad. Sci. USA 89(21), 10046-10050 (1992).
101. Singh S, Zlotnick A: Observed hysteresis of virus capsid disassembly is implicit in kinetic models of assembly. J. Biol. Chem. 278(20), 18249-18255 (2003).
102. Zlotnick A, Stray SJ: How does your virus grow? Understanding and interfering with virus assembly. Trends Biotechnol. 21(12), 536-542 (2003).
103. Zlotnick A: Distinguishing reversible from irreversible virus capsid assembly. J. Mol. Biol. 366(1), 14-18 (2007).
104. Deres K, Schröder CH, Paessens A et al.: Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299(5608), 893-896 (2003).
105. Stray SJ, Zlotnick A: BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. J. Mol. Recognit. 19(6), 542-548 (2006).
106. Bourne CR, Finn MG, Zlotnick A: Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1. J. Virol. 80(22), 11055-11061 (2006).
107. Shi C, Wu CQ, Cao AM, Sheng HZ, Yan XZ, Liao MY: NMR-spectroscopy-based metabonomic approach to the analysis of Bay4l-4109, a novel and-HBV compound, induced hepatotoxicity in rats. Toxicol, Lett. 173(3), 161-167 (1007).
108. Zlotnick A, Lee A, Bourne CR, Johnson JM, Domanico PL, Stray SJ: In vitro screening for molecules that affect virus capsid assembly, (and other protein association reactions). Nat. Protoc. 2(3), 490-498 (2007).
109. Vogel M, Diez M, Eisfeld J, Nassal M: In vitro assembly of mosaic hepatitis B virus capsid-like particles (CLPs): rescue into CLPs of assembly-deficient core protein fusions and FRET-suited CLPs. FEBS Lett. 579(23), 5211-5216 (2005).
110. Perlman DH, Berg EA, O'Connor PB, Costello CE, Hu J: Reverse transcription-associated dephosphorylation of hepadnavirus nucleocapsids. Proc. Natl Acad. Sci. USA 102(25), 9020-9025 (2005).
111. Basagoudanavar SH, Perlman DH, Hu J: Regulation of hepadnavirus reverse transcription by dynamic nucleocapsid phosphorylation. J. Virol. 81(4), 1641-1649 (2007).
112. Röler C, Köck J, Kann M et al.: APOBEC-mediated interference with hepadnavirus production. Hepatology 42(2), 301-309 (2005).
113. Nguyen DH, Hu J: Reverse transcriptase- and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids. J. Virol. 82(14), 6852-6861 (2008).
114. Gripon P, Cannie I, Urban S: Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J. Virol. 79(3),1613-1622 (2005),
115. Petersen J, Dandri M, Mier W et al.: Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat. Biotechnol. 26(3), 335-341 (2008).
116. Weissenhorn W, Hinz A, Gaudin Y: Virus membrane fusion. FEBS Lett. 581 (11), 2150-2155 (2007).
117. Simsek E, Lu X, Ouzounov S, Block TM, Mehta AS: α-glucosidase inhibitors have a prolonged antiviral effect against hepatitis B virus through the sustained inhibition of the large and middle envelope glycoproteins. Antivir. Chem. Chemother. 17(5), 259-267 (2006).
118. Durantel D, Alotte C, Zoulim F: Glucosidase inhibitors as antiviral agents for hepatitis B and C. Curr. Opin Investig. Drugs 8(2), 125-129 (2007).
119. Vigerust DJ: Pathobiology of virus glycosylation: implications to disease and prospects for treatment. Future Virol. 2(6), 615-623 (2007).
120. Lazar C, Durantel D, Macovei A et al.: Treatment of hepatitis B virus-infected cells with α-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. Antiviral Res. 76(1), 30-37 (2007).
121. Block TM, Lu X, Mehra AS et al.: Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat. Med. 4(5), 610-614 (1998).
122. Prasad KK, Toraskar MP, Kadam VJ: N-myristoyltransferase: a novel target. Mini Rev. Med. Chem. 8(2), 142-149 (2008).
123. Chen HS, Kaneko S, Girones R et al.: The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J. Virol. 67(3), 1218-1226 (1993).
124. Zoulim F, Saputelli J, Seeger C: Woodchuck hepatitis virus X protein is required for viral infection in vivo. J. Virol. 68(3), 2026-2030 (1994).
125. Zhang Z, Torii N, Hu Z, Jacob J, Liang TJ: X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo. J. Clin. Invest. 108(10), 1523-1531 (2001).
126. Bouchard MJ, Schneider RJ: The enigmatic X gene of hepatitis B virus. J. Virol. 78(23), 12725-12734 (2004).
127. Cougot D, Wu Y, Cairo S et al.: The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. J. Biol. Chem. 282(7), 4277-4287 (2007).
128. Liu X, Wang L, Zhao K et al.: The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451(7180), 846-850 (2008).
129. McClain SL, Clippinger AJ, Lizzano R. Bouchard MJ: Hepatitis B virus replication is associated with an HBx-dependent mitochondrion-regulated increase in cytosolic calcium levels. J. Virol. 81(21), 12061-12065 (2007).
130. Werle-Lapostolle B, Bowden S, Locarnini S et al.: Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126(7), 1750-1758 (2004).
131. Zoulim F: New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J. Hepatol. 42(3), 302-308 (2005).
132. Mason WS, Litwin S, Xu C, Jilbert AR: Hepatocyte turnover in transient and chronic hepadnavirus infections. J. Viral. Hepat. 14(Suppl. 1), 22-28 (2007).
133. Zhang YY, Zhang BH, Theele D, Litwin S, Toll E, Summers J: Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver. Proc. Natl Acad. Sci. USA 100(21),12372-12377 (2003).
134. Wieland SF, Eustaquio A. Whitten-Bauer C, Boyd B, Chisari FV: IFN prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc. Natl Acad. Sci. USA 102(28), 9913-9917 (2005).
135. Jacquard AC, Nassal M, Pichoud C et al.: Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of γ-lFN in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. 48(7), 2683-2692 (2004).
136. Zhu Y, Cullen JM, Aldrich CE et al.: Adenovirus-based gene therapy during clevudine treatment of woodchucks chronically infected with woodchuck hepatitis virus. Virology 327(1), 26-40 (2004).
137. Summers J, Mason WS: Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc. Natl Acad. Sci. USA 101 (2), 638-640 (2004).
138. Raney AK Eggers CM, Kline EF et al.: Nuclear covalently closed circular viral genornic DNA in the liver of hepatocyte nuclear factor 1 α-null hepatitis B virus transgenic mice. J. Virol. 75(6),2900-2911 (2001).
139. Bock CT, Schwinn S, Locarnini S et al.: Structural organization of the hepatitis B virus minichromosome. J. Mol. Biol. 307(1), 183-196 (2001).
140. Pollicino T, Belloni L, Raffa G et al.: Hepatitis B virus replication is regulated by the acetylation status of heparitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130(3), 823-837 (2006).
141. Lilley CE, Schwartz RA, Weitzman MD: Using or abusing: viruses and the cellular DNA damage response. Trends Microbiol. 15(3), 119-126 (2007).
142. Wang JC: Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 3(6), 430-440 (2002).
143. Connelly JC, Leach DR: Repair of DNA covalently linked to protein. Mol. Cell 13(3), 307-316 (2004).
144. Ding J, Miao ZH, Meng LH, Geng MY: Emerging cancer therapeutic opportunities target DNA-repair systems. Trends Pharmacol. Sci. 27(6), 338-344 (2006).
145. Gao W, Hu J: Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J. Virol. 81(12), 6164-6174 (2007).
146. Guo H, Jiang D, Zhou T, Cuconati A, Block TM, Guo JT. Characterization of the DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J. Virol. 81(22), 12472-12484 (2007).
147. Stray SJ, Johnson JM, Kopek BG, Zlotnick A: An in vitro fluorescence screen to identify antivirals that disrupt hepatitis B virus capsid assembly. Nat. Biotechnol. 24(3), 358-362 (2006).